Evidence map›Paper›PMID 32352753›Full record

ArticleACS chemical biology2020

Dual Neutral Sphingomyelinase-2/Acetylcholinesterase Inhibitors for the Treatment of Alzheimer's Disease.

Tina Bilousova, Bryan J Simmons, Rachel R Knapp, Chris J Elias, Jesus Campagna, Mikhail Melnik, Sujyoti Chandra, Samantha Focht, Chunni Zhu, Kanagasabai Vadivel and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Neutral sphingomyelinase 2: A promising drug target for CNS disease.Advances in pharmacology (San Diego, Calif.) · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Neutral sphingomyelinase-2 and cardiometabolic diseases.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2021
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tina BilousovaDrug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, California 90095, United States.
Bryan J SimmonsDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.
Rachel R KnappDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.
Chris J EliasDrug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, California 90095, United States.
Jesus CampagnaDrug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, California 90095, United States.
Mikhail MelnikSchool of Nursing, University of California, Los Angeles, California 90095, United States.
Sujyoti ChandraDrug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, California 90095, United States.
Samantha FochtDrug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, California 90095, United States.
Chunni ZhuDrug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, California 90095, United States.
Kanagasabai VadivelDrug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, California 90095, United States.
Barbara JagodzinskaDrug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, California 90095, United States.
Whitaker CohnDrug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, California 90095, United States.
Patricia SpilmanDrug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, California 90095, United States.
Karen H GylysSchool of Nursing, University of California, Los Angeles, California 90095, United States.
Neil K GargDepartment of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States.ORCID 0000-0002-7793-2629
Varghese JohnDrug Discovery Laboratory, Department of Neurology, Mary S. Easton Center for Alzheimer's Disease Research, University of California, Los Angeles, California 90095, United States.ORCID 0000-0001-7675-2426

Funding

ApoE4-targeted therapeutics that normalize SirT1R01AG051386 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JOHN, VARGHESE · 2015 to 2019
$3.0M
Small molecule mimetics of Humanin that normalize neuronal p-Akt as novel therapeutics for ADRF1AG068116 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JOHN, VARGHESE · 2021 to 2023
$2.1M
Tau pathology in neurons, glia, and cell type-specific exosomes from cryopreserved AD cortexR21AG063767 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BILOUSOVA, TINA, GYLYS, KAREN H · 2020 to 2020
$429k
Time-of-Flight Mass Spectrometer for Synthesis Supporting Biomedical ResearchS10RR025631 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HOUK, KENDALL N · 2009 to 2009
$328k
NCRR NIH HHS S10 RR025631NIA NIH HHS R01 AG051386NIA NIH HHS R21 AG063767NIA NIH HHS RF1 AG068116
6 · The paper itself

Abstract

We report the discovery of a novel class of compounds that function as dual inhibitors of the enzymes neutral sphingomyelinase-2 (nSMase2) and acetylcholinesterase (AChE). Inhibition of these enzymes provides a unique strategy to suppress the propagation of tau pathology in the treatment of Alzheimer's disease (AD). We describe the key SAR elements that affect relative nSMase2 and/or AChE inhibitor effects and potency, in addition to the identification of two analogs that suppress the release of tau-bearing exosomes

Indexed as

AcetylcholinesteraseAlzheimer DiseaseCholinesterase InhibitorsEnzyme InhibitorsHumansSphingomyelin PhosphodiesteraseStructure-Activity RelationshipAcetylcholinesteraseCholinesterase InhibitorsEnzyme InhibitorsSphingomyelin Phosphodiesterase

Identifiers

PMID32352753
PMCPMC8297715

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.